Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
复制标题
DOI：
10.18632/oncotarget.12696
复制
发表时间：
2016-12-13
期刊：
影响因子：
--
通讯作者：
Matsushita K
中科院分区：
文献类型：
--
作者：
Kobayashi S;Hoshino T;Hiwasa T;Satoh M;Rahmutulla B;Tsuchida S;Komukai Y;Tanaka T;Matsubara H;Shimada H;Nomura F;Matsushita K
皮肌炎和干燥综合征患者血清中存在抗PUF 60（poly（U）-binding-splicing factor，多聚体结合-剪接因子）自身抗体，这些疾病有时与恶性肿瘤有关。PUF 60与c-myc基因转录抑制子远上游元件结合蛋白相互作用抑制子（FIR）相同。在结直肠癌中，缺少外显子2的FIR剪接变体（FIRΔ外显子2）作为FIR的显性阴性形式过表达。为了揭示抗FIR（FIR/FIRΔ exon 2）抗体在癌症中的存在和意义，本研究在结直肠癌和其他癌症患者的血清中进行了探索。28例结直肠癌患者术前血清中抗FIRs抗体阳性率为32.2%，明显高于健康对照组（Mann-Whitney U检验，p < 0.01）。术后抗FIRs抗体水平明显下降（p < 0.01）。在未检测到抗p53抗体、CEA和CA 19 -9的早期和/或复发性结肠癌患者的血清中以及在其他癌症患者的血清中检测到抗FIRs抗体。此外，抗FIRs抗体的受试者操作特征曲线下面积（0.85）显著大于抗p53抗体或CA 19 -9。总之，抗FIRs抗体与其他临床可用的肿瘤标志物的组合进一步提高了癌症诊断的特异性和准确性。
Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren's syndrome that occasionally associated with malignancies. PUF60 is identical with far-upstream element-binding protein-interacting repressor (FIR) that is a transcriptional repressor of c-myc gene. In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRΔexon2) is overexpressed as a dominant negative form of FIR. In this study, to reveal the presence and the significance of anti-FIRs (FIR/FIRΔexon2) antibodies in cancers were explored in the sera of colorectal and other cancer patients. Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera (Mann–Whitney U test, p < 0.01). The level of anti-FIRs antibodies significantly decreased after the operation (p < 0.01). Anti-FIRs antibodies were detected in the sera of early-stage and/or recurrent colon cancer patients in which anti-p53 antibodies, CEA, and CA19-9 were not detected as well as in the sera of other cancer patients. Furthermore, the area under the curve of receiver operating characteristic for anti-FIRs antibodies was significantly larger (0.85) than that for anti-p53 antibodies or CA19-9. In conclusions, the combination of anti-FIRs antibodies with other clinically available tumor markers further improved the specificity and accuracy of cancer diagnosis.